neovascular

SPHINX31 is a potent inhibitor of serine/arginine-rich protein kinase 1 (SRPK1; IC50: 5.9 nM).

Deferoxamine Mesylate (DFOM) is an iron chelator and ferroptosis inhibitor. Deferoxamine Mesylate binds free iron into a stable complex and reduces iron accumulation. Deferoxamine Mesylate up-regulates HIF-1α levels and induces apoptosis.

INCA-6 (Triptycene-1,4-quinone) is a cell-permeable NFAT inhibitor that disrupts CN-NFAT signaling by targeting the NFAT(P) substrate at the calcineurin (CN) phosphatase site.

Bucillamine (DE019) protects against Ischemia/reperfusion injury in high-risk organ transplants and inhibits the production of VEGF. Bucillamine is an orally active sulfhydryl donor and antioxidant with antirheumatic and antiangiogenic properties. Bucillamine can be used for studies about choroidal neovascularization and rheumatoid arthritis.

JP-153 is an inhibitor of Src-FAK-Paxillin signaling. It suppresses Src-dependent phosphorylation of paxillin (Y118) and subsequent activation of Akt (S473). JP-153 reduces VEGF-induced migration and proliferation of retinal endothelial cells and is applicable in the study of neovascular eye diseases.

Umedaptanib pegol is a nucleic acid aptamer that targets and inhibits fibroblast growth factor-2 (FGF2). It is currently under investigation for its potential use in the treatment of neovascular age-related macular degeneration (nAMD).

Umedaptanib pegol is a nucleic acid aptamer targeting anti-fibroblast growth factor-2 (FGF2), and it is utilized in the research of neovascular age-related macular degeneration (nAMD).

ALK4290 (AKST4290) is a potent, orally active CCR3 inhibitor (compound Example 2) with a Ki of 3.2 nM for hCCR3[1], suitable for research into neovascular age-related macular degeneration and Parkinsonism[2][3].

AG-13958 monohydrochloride is the HCl salt of AG-13958 --- a VEGFA inhibitor potentially for the treatment of age-related macular degeneration. Neovascular AMD, a subtype characterized by the growth of new, pathologic blood vessels, results in most of the cases of severe and rapid vision loss associated with AMD. A critical activator of angiogenesis in neovascular AMD is VEGF.

Brolucizumab (DLX1008) is a single-chain variable fragment (scFv) anti-VEGF-A antibody exhibiting an exceptionally low picomolar binding affinity (K D = 1.05 pM). through its potent blockade of vascular endothelial growth factor A (VEGF-A), Brolucizumab effectively reduces pathological neovascularization and vascular leakage within the macula and is under investigation for the treatment of neovascular (wet) age-related macular degeneration (AMD).

Cyclo(RGDyC), a cyclic pentapeptide, exhibits anti-angiogenic properties and has been investigated in conjunction with liposomal delivery systems for the study of ocular neovascular diseases and cancer [1] [2].

ALK4290 dihydrochloride (AKST4290 dihydrochlorid) serves as a potent and orally active inhibitor of CCR3, exhibiting a K i of 3.2 nM for hCCR3 [1]. It is primarily used in research related to neovascular age-related macular degeneration and Parkinsonism [2] [3].

CM101 is an anti-pathogenic angiogenic polysaccharide derived from Group B Streptococcus. It inhibits inflammatory angiogenesis, accelerates wound healing in mouse models, and reduces scar formation post-spinal cord injury. Additionally, CM101 rapidly induces tumor neovascular inflammation, promotes inflammatory cell infiltration, suppresses tumor growth, and induces tumor apoptosis (apoptosis).

DSPE-PEG2000-cRGD is a PEG compound composed of DSPE and an αvβ3-targeting peptide (cRGD). The cRGD peptide specifically binds to αvβ3 on the surface of various cancer cells and neovascular cells. This compound can be utilized for drug delivery.